BACKGROUND: Testicular cancer survivors (TCS) have an increased risk of treatment-related cardiovascular disease (CVD), which may limit their overall survival. We evaluated the effects of high-intensity aerobic interval training (HIIT) on traditional and novel CVD risk factors and surrogate markers of mortality in a population-based sample of TCS. METHODS: This phase 2 trial (ClinicalTrials.gov identifier NCT02459132) randomly assigned 63 TCS to usual care (UC) or 12 weeks of supervised HIIT (ie, alternating periods of vigorous-intensity and light-intensity aerobic exercise). The primary outcome was peak aerobic fitness (VO 2peak ) assessed via a treadmill-based maximal cardiorespiratory exercise test. Secondary endpoints included CVD risk (eg, Framingham Risk Score), arterial health, parasympathetic nervous system function, and blood-based biomarkers. RESULTS: Postintervention VO 2peak data were obtained for 61 participants (97%). HIIT participants attended 99% of the exercise sessions and achieved 98% of the target exercise intensity. Analysis of covariance demonstrated that HIIT was superior to UC for improving VO 2peak (adjusted between-group mean difference, 3.7 mL O 2 /kg/min; 95% confidence interval, 2.4-5.1 [P<.001]) and multiple secondary outcomes including CVD risk (P 5.011), arterial thickness (P<.001), arterial stiffness (P<.001), postexercise parasympathetic reactivation (P 5.001), inflammation (P 5.045), and low-density lipoprotein (P 5.014). Overall, HIIT reduced the prevalence of modifiable CVD risk factors by 20% compared with UC. CONCLUSIONS: This randomized trial provides the first evidence that HIIT improves cardiorespiratory fitness, multiple pathways of CVD risk, and surrogate markers of mortality in TCS. These findings have important implications for the management of TCS. Further research concerning the long-term effects of HIIT on CVD morbidity and mortality in TCS is warranted. Cancer 2017;123:4057-65. V C 2017 American Cancer Society.
INTRODUCTION
Testicular cancer (TC) is the most commonly diagnosed malignancy in men aged 15 to 35 years 1 and the incidence has been rising for >20 years. 2 Although germ cell disease is highly curable, with 5-year relative survival rates approaching 97%, 3 each of the conventional therapies used to treat TC contribute to an increased risk of subclinical and overt cardiovascular disease (CVD) in TC survivors (TCS). 4 As reviewed elsewhere, 4 orchiectomy-related subclinical/overt hypogonadism, chemotherapy-related vascular injury (extending > 20 years posttreatment) 5 , and metabolic disturbances (associated with all TC treatment modalities) all likely contribute to an increased CVD risk in TCS. 4 Together, if untreated, these long-term disturbances present a chronic stimulus for the development of atherosclerotic disease 4, 6 and may impact the overall survival of TCS. Strategies to mitigate the effects of these therapies on CVD risk in TCS are urgently needed.
Aerobic exercise training improves CVD risk factors and surrogate markers of mortality in numerous populations, 7, 8 including some cancer survivor groups, 9, 10 and has been proposed as a potential countermeasure with which to mitigate CVD risks in TCS. 4 However, the mechanisms underlying increased CVD risk are fundamentally different in TCS (ie, treatment-related vs lifestyle-related factors), thereby making it difficult to extrapolate the same degree of benefit from other populations to TCS. Compared with other modalities of aerobic exercise, high-intensity aerobic interval training (HIIT) involves alternating periods of vigorousintensity and light-intensity exercise; and, it has been shown to elicit the greatest magnitudes of improvement across traditional and novel CVD risk factors. 8 Chief among these effects is an improvement in peak aerobic fitness (VO 2peak ), which is among the most robust surrogate markers of human health, longevity, and CVD risk. 7, 11 Given the multiple competing drivers of CVD risk (eg, vascular injury, metabolic syndrome, and hypogonadism), VO 2peak may be the best single measure of global cardiovascular health in TCS.
Recent observational evidence in TCS treated with cisplatin 12 suggests that vigorous physical activity is protective against adverse health outcomes including CVD; however, to the best of our knowledge, no randomized evidence exists demonstrating the causal effects of aerobic exercise training on reducing CVD risks in TCS. The purpose of the High-Intensity Interval Training in Testicular cancer Survivors (HIITTS) trial was to evaluate the impact of HIIT on the established pathways of treatmentrelated CVD risk in TCS. We hypothesized that 12 weeks of HIIT would be superior to usual care (UC) for improving VO 2peak . We also hypothesized that, compared with UC, HIIT would elicit significant improvements in novel CVD risk factors and markers of atherogenesis, including arterial wall thickness, central and peripheral arterial stiffness, parasympathetic nervous system function, and blood-based markers of inflammation and endothelial health.
MATERIALS AND METHODS
Full details of the HIITTS trial methods are provided in the Supporting Information.
Participants
Participants were recruited via mail (using the Alberta Cancer Registry) and from the surveillance clinic at the Cross Cancer Institute in Edmonton, Alberta, Canada. Men aged 18 to 80 years with a confirmed history of TC and no evidence of precancer CVD were eligible. Men were excluded if they were unable to complete the first 2 stages of the exercise test, had any psychiatric condition impairing their ability to perform the exercise, had any uncontrolled cardiovascular condition, or already performed regular vigorous aerobic exercise. The HIITTS trial received ethical approval from the Health Research Ethics Board of Alberta Cancer Committee (Trial ID 14-0183) and the University of Alberta (ClinicalTrials.gov identifier NCT02459132).
Study Design and Randomization
The HIITTS trial was a prospective 2-armed, phase 2, randomized controlled trial. Consenting participants were stratified by age (aged < 50 years vs aged ! 50 years) and treatment exposure (surgery only vs radiotherapy/chemotherapy/both) and randomized to HIIT or UC using a 1:1 ratio and a variable 4 to 6 permuted block design. The allocation sequence was produced via computer-generated random numbers and concealed from staff involved in recruitment and baseline testing.
Exercise Training and UC Conditions
Participants randomly assigned to HIIT were asked to attend thrice-weekly supervised exercise sessions consisting of uphill treadmill walking/running and to maintain other low-intensity to moderate-intensity exercise they were performing at baseline. HIIT sessions began with a 5-minute warm-up (performed at 6 5% of the ventilatory threshold calculated from a maximal exercise test), transitioned to the work period, and ended with a 5-minute cooldown (total of 35 minutes). During the work period, participants completed 4 high-intensity intervals lasting 4 minutes each, which progressed from 75% to 95% of VO 2peak over the intervention period. High-intensity intervals were separated by 3-minute active recovery intervals (performed 5%-10% below the ventilatory threshold). Exercise intensity was monitored using heart rate (HR) monitors, and programs were augmented to maintain target HRs. Participants randomly assigned to the UC group were asked not to initiate HIIT and to maintain their baseline exercise levels. Using a waitlist control design, UC participants were offered a 6-week supervised HIIT program after the 12-week observation period and 3-month follow-up assessment.
Assessment Protocol
Within the 48-hour period before testing, participants had their blood drawn in a fasting state (!12 hours) after avoiding exercise (!8 hours); vasoactive medications (!5 half-lives); and the consumption of caffeine, vitamin C, alcohol, and tobacco (!8 hours). 13 On test days, participants arrived in the same fasting state. Participants first completed the resting portion of the testing protocol (approximately 2 hours), were fed while they completed their baseline questionnaire (approximately 45 minutes), and finished with a maximal exercise test (approximately 1 hour).
Assessment of Primary and Secondary Endpoints

Exercise assessments
Our primary outcome, aerobic fitness (relative VO 2peak ), was assessed via a treadmill-based maximal cardiorespiratory exercise test (4Front; Woodway, Waukesha, Wisconsin) with a constant individualized belt speed and an incline increasing by 2% every 2 minutes until exhaustion. During the test, oxygen uptake (TrueOne 2400; ParvoMedics, Murray, Utah) and HR (12-lead electrocardiogram) (CardioCard; Nasiff, Central Square, New York) were measured continuously. VO 2peak was defined as the highest oxygen uptake value recorded during the test. Data are presented as the relative (primary outcome) and absolute VO 2peak . Ventilatory threshold was used to prescribe exercise intensities. HR was measured for an additional 6 minutes of recovery (first minute standing plus 5 minutes of active recovery). One-minute HR recovery (an index of postexercise parasympathetic reactivation 14 ) was calculated as the difference in HR between peak exercise and after 1 minute of quiet treadmill standing immediately after the test.
Resting hemodynamic, vascular, and nervous system assessments Participants were tested under the same conditions (eg, ! 12-hour fast) as when their blood specimen was collected. 13 Participants began resting in a quiet, darkened room for 30 minutes. During the rest period, carotid plaque burden was assessed via bilateral ultrasound scans of the near and far walls of the common carotid, carotid bifurcation, and internal carotid arteries, as per the Mannheim Consensus Guidelines. 15 Immediately after the rest period, bilateral carotid artery intima-media thickness (ie, arterial wall thickness) was measured via ultrasound. 15 Carotid distensibility, an index of local arterial stiffness, was calculated as the average difference between maximum (systolic) and minimum (diastolic) arterial cross-sectional areas (assessed via ultrasound), normalized to brachial pulse pressure. 16 Left brachial artery structure, endothelial function, and microvascular function were assessed via flow-mediated dilation (FMD), as per best practice guidelines. 13 FMD was calculated as the percentage increase in arterial diameter from baseline to peak 13 and then was normalized for the total shear rate stimulus. 13, 17 Two markers of microvascular function and independent predictors of CVD risk (ie, velocity time integral and shear stress during reactive hyperemia) 18 were calculated using blood velocity data collected during the FMD protocol. Respiratory sinus arrhythmia (an index of parasympathetic function) was assessed by measuring the magnitude of heart period variability during a paced deep-breathing challenge. 19 Central arterial stiffness (ie, carotid-femoral pulse wave velocity [PWV] ) and peripheral arterial stiffness (ie, femoral-toe PWV) were assessed via applanation tonometry (SPT-301 Pulse Wave Tonometer; Millar Instruments, Houston, Texas), as per best practice guidelines. 20 Using the foot-to-foot method, 20 the velocity of each pulse wave was calculated as the time difference between the arrival of the blood pressure waveform at each site of the central and peripheral arterial segments.
Blood-based biomarker assessments
Blood specimen collection took place at various DynaLife laboratories between Edmonton and Red Deer in the province of Alberta, Canada. Each specimen was immediately stored, shipped, and analyzed at a central processing facility. Anonymized results were e-mailed directly to the study coordinator within 48 hours of collection and interpreted as per national standards. 21 
Cardiovascular disease risk assessments
The Framingham 10-year CVD risk score and vascular age were used to estimate CVD risk and were calculated using the general cardiovascular risk profile criteria for the Framingham Heart Study. 22 The modifiable CVD risk factor score (MRFS) was used as an index of total CVD risk and incorporated 24 novel and traditional surrogate markers of cardiovascular morbidity and mortality risk.
Statistical Analyses and Sample Size Calculation
Data cleaning, processing, and analyses were either conducted or verified by a research assistant blinded to group allocation. With 33 participants per group (total of 66 participants), and using an analysis of covariance to adjust for baseline values and relevant covariates, we had 80% power to detect a 3.5-mL O 2 /kg/minute between-group difference in VO 2peak based on a standard deviation of 5.8 mL O 2 /kg/ minute. We reported unadjusted baseline data and adjusted postintervention data, mean between-group differences, 95% confidence intervals, and P values for all hypothesized comparisons. Data were analyzed using an intention-totreat approach (SPSS statistical software, version 24; IBM Corporation, Armonk, New York). No missing data strategy was used given the minimal amount of missing data.
RESULTS
Participant Flow
Participants were recruited from June 2015 to March 2016. Of the 948 potentially eligible participants contacted, 108 (11%) were screened for eligibility and 63 (7%) were randomized (see Fig. 1 for full details). We obtained postintervention VO 2peak data on 61 participants (97%).
Baseline Characteristics and Participant Adherence
Participant demographic, medical, and behavioral profiles are shown in Table 1 . The groups were balanced with regard to baseline descriptive variables. Exercise adherence data are described in Table 2 . Participants completed 99% of all exercise sessions and achieved 98% and 103%, respectively, of their target HRs during the work and active recovery periods. No exercise-related adverse events were reported or observed. No changes in self-directed exercise from baseline were reported in either group. Abbreviations: bpm, beats per minute; HIIT, high-intensity aerobic interval training; VO 2peak , peak aerobic fitness; W:R, work period:rest period (active recovery). a Target/achieved heart rates reflect group averages during each phase. Recovery intensity was set at 10% less than the estimated ventilatory threshold. Abbreviations: 95% CI, 95% confidence interval; Adj, adjusted; bpm, beats per minute; HIIT, high-intensity aerobic interval training; kPa: kilopascals; m/s, meters per second; PWV, pulse wave velocity; SD, standard deviation; SE, standard error; SSRH, shear stress during reactive hyperemia; TCS, testicular cancer survivors; VO 2peak , peak aerobic fitness. a Follow-up and between-group difference values were adjusted for baseline value of the outcome, age, treatment exposure, and time since treatment. b Also adjusted for change in mean arterial pressure. c Also adjusted for change in arterial diameter. d Also adjusted for change in intima-media thickness. e Also adjusted for change in shear rate. f Unadjusted and adjusted group means, SDs, SEs, and 95% CIs were multiplied by a factor of 1000 for display purposes. g Also adjusted for change in heart rate.
Primary and Secondary Endpoints
[P<.001]). Compared with UC, HIIT increased absolute VO 2peak (P<.001), HR recovery (P 5 .001), and respiratory sinus arrhythmia (P 5 .033), and decreased resting HR (P 5 .012) and diastolic blood pressure (P 5 .013). Table 4 reports the changes in vascular structure and function. Compared with UC, HIIT significantly reduced carotid intima-media thickness (average, P<.001; maximum, P<.001), increased carotid distensibility (P 5 .049), decreased arterial stiffness (carotid-femoral PWV: P<.001; and femoral-toe PWV: P 5 .001), increased brachial artery diameter (P 5 .009), and improved microvascular reactivity (velocity time integral; P 5 .039). Table 5 shows the changes in blood-based biomarkers. HIIT significantly decreased high-sensitivity C-reactive protein (P 5 .045) and low-density lipoprotein (P 5 .014) compared with UC. Table 6 reports the changes in CVD risk. HIIT caused a significant reduction in the Framingham 10-year CVD risk score (P 5 .011), vascular age (P 5 .011), and the MRFS (P 5 .002).
DISCUSSION
To our knowledge, HIITTS is the first randomized trial to demonstrate significant and potentially clinically meaningful improvements in CVD risk factors and surrogate markers of mortality in TCS. As hypothesized, HIIT significantly improved VO 2peak by 3.7 mL/kg/minute 23 Moreover, this magnitude of improvement is likely clinically significant because each 3.5-mL O 2 /kg/minute improvement in VO 2peak is associated with a 10% to 25% relative risk reduction in overall mortality. 24 Furthermore, in healthy men, VO 2peak declines an average of 10% per decade. 25 Therefore, the relative HIIT-related VO 2peak improvement of approximately 10% achieved in the current trial represents the reversal of nearly a decade's worth of cardiorespiratory aging.
HIIT also caused significant and pathophysiologically relevant improvements in multiple CVD risk factors, accounting for a 20% reduction from baseline in the MRFS. Specifically, HIIT caused concurrent improvements in pathways of atherosclerotic CVD development including arterial stiffness, arterial thickness, microvascular reactivity, parasympathetic function, inflammation, and dyslipidemia. It is interesting to note that the consistent HIIT-related improvement across indices of parasympathetic tone/reactivity 14 may have important pathophysiological implications because decreased parasympathetic activity predisposes affected individuals to exaggerated proinflammatory responses and endothelial dysfunction (2 principle drivers of atherogenesis). 26, 27 Not only are markers of parasympathetic function strong predictors of mortality, 14, 26 preliminary evidence has indicated a survival advantage for those who improved markers of parasympathetic function with 12 weeks of aerobic exercise-based cardiac rehabilitation. 28 Overall, the pattern of HIIT-related benefit was consistent with the majority of the major mechanisms of increased CVD morbidity and mortality risks in TCS. 4 It is important to note that comparable improvements in these outcomes within other clinical populations are associated with relative risk reductions of 10% to 30% for CVD-related and overall mortality. 24, 28, 29 Although HIIT did not improve all CVD risk factors (eg, FMD, potentially owing to arterial remodeling or follow-up assessment timing [training adaptations may peak at 3-4 weeks] 30 ), the findings of the current study provide strong preliminary support that HIIT may mitigate cancerrelated cardiovascular morbidity and mortality in TCS.
The HIITTS trial has several notable strengths and limitations. To the best of our knowledge, HIITTS is the first randomized aerobic exercise trial in TCS and provides among the most comprehensive cardiovascular risk assessment in exercise oncology research to date. The near-perfect participant adherence rates and absence of adverse events suggest that HIIT is safe and feasible for TCS. Despite the self-selection sampling bias inherent to exercise research, our unselected population-based sampling approach (ie, the inclusion of participants with varied treatment exposures) may portend even larger effects in more targeted subgroups of TCS at high risk of CVD. Moreover, the inclusion of traditional and novel CVD risk factors facilitates a more comprehensive characterization of CVD risk in TCS and helps to justify expanding CVD risk screening parameters in TCS. Limitations of the HIITTS trial include the lack of postintervention outcome assessor blinding, 11% response rate, short follow-up period, variable time since diagnosis, and use of surrogate markers instead of clinical cardiovascular events/mortality rates.
We believe the findings of the HIITTS trial provide robust phase 2 evidence that 12 weeks of HIIT results in significant improvements in important CVD risk factors and surrogate markers of mortality in TCS. The fact that HIIT caused concurrent improvements across multiple pathways of CVD risk suggests that it may be an effective therapeutic intervention for mitigating long-term CVD risks in TCS and has important implications for the management of these patients. Further investigation of the potential for long-term HIIT to reduce cardiovascular morbidity and mortality in TCS is warranted.
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